Phaseline

Companies › Pharvaris Netherlands

Pharvaris Netherlands: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 3; Immunology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Deucrictibant
Plasma kallikrein inhibitor
KLKB1Phase 3Hereditary Angioedema (HAE); Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)Jun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06669754DeucrictibantPhase 3Hereditary Angioedema (HAE)ImmunologyJul 2026
NCT07266805DeucrictibantPhase 3Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)ImmunologyJun 2027

Targets

KLKB1 (1)

Companies with the same targets

Kyowa Kirin KalVista Pharmaceuticals BioCryst Pharmaceuticals ADARx Pharmaceuticals DiaMedica Therapeutics

Companies built like this

KalVista Pharmaceuticals BioCryst Pharmaceuticals AUG Therapeutics Lynk Pharmaceuticals Fujian Mindong Rejuvenation Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.